ASPARAGINASE
Lymphoma, Lymphoblastic
Therapeutic Advances in Childhood Leukemia Consortiumprotein_peptidePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 61/ 100
- Competitive Position
- 95/ 100
Competitive context
83 Active assets in the Lymphoma, Lymphoblastic cohort.
View all 50 →
Same molecule, other indications
ASPARAGINASE is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →